Scholarlink

Background <p>The rising occurrence of antibiotic resistance in <i>Staphylococcus aureus</i> significantly complicates its treatment. Endolysins are now recognized as a promising substitute for antibiotics in combating multidrug-resistant bacteria. In this research, a novel chimeric endolysin named ZAM-CS was engineered and assessed to achieve enhanced stability, solubility, and rapid bactericidal activity. This was accomplished by combining the catalytic domain of the SAL-1 endolysin with the peptidoglycan binding domain of lysostaphin.</p> Results <p>Expression and purification outcomes indicated that ZAM-CS exhibited significant solubility, with a yield of approximately 23&#xa0;mg/L. ZAM-CS demonstrated high stability under various temperature conditions and retained most of its activity in both acidic and alkaline pH. The results of turbidity reduction assay showed a 50% decrease in the initial OD600 within 10&#xa0;min at a minimum concentration of 2&#xa0;µg/mL. The minimum inhibitory concentration and the minimum bactericidal concentration values of ZAM-CS are identical in the methicillin-resistant <i>Staphylococcus aureus</i> strain, indicating the strong bactericidal properties of this endolysin. Antimicrobial tests showed ZAM-CS was also effective against coagulase-negative <i>Staphylococci</i>, <i>Streptococcus agalactiae</i>, and <i>Enterococcus faecalis</i>.</p> Conclusion <p>The rapid and dynamic action and high stability of ZAM-CS compared to other recombinant endolysins make it a suitable candidate for development to replace antibiotics targeting harmful <i>Staphylococci</i>, including MRSA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ZAM-CS, a novel chimeric endolysin with enhanced stability and rapid action against methicillin-resistant Staphylococcus aureus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月7日

查看全文
  • Yasaman Ahmadbeigi,
  • Neda Soleimani,
  • Farzaneh Azizmohseni,
  • Zahra Amini-Bayat

摘要

Background

The rising occurrence of antibiotic resistance in Staphylococcus aureus significantly complicates its treatment. Endolysins are now recognized as a promising substitute for antibiotics in combating multidrug-resistant bacteria. In this research, a novel chimeric endolysin named ZAM-CS was engineered and assessed to achieve enhanced stability, solubility, and rapid bactericidal activity. This was accomplished by combining the catalytic domain of the SAL-1 endolysin with the peptidoglycan binding domain of lysostaphin.

Results

Expression and purification outcomes indicated that ZAM-CS exhibited significant solubility, with a yield of approximately 23 mg/L. ZAM-CS demonstrated high stability under various temperature conditions and retained most of its activity in both acidic and alkaline pH. The results of turbidity reduction assay showed a 50% decrease in the initial OD600 within 10 min at a minimum concentration of 2 µg/mL. The minimum inhibitory concentration and the minimum bactericidal concentration values of ZAM-CS are identical in the methicillin-resistant Staphylococcus aureus strain, indicating the strong bactericidal properties of this endolysin. Antimicrobial tests showed ZAM-CS was also effective against coagulase-negative Staphylococci, Streptococcus agalactiae, and Enterococcus faecalis.

Conclusion

The rapid and dynamic action and high stability of ZAM-CS compared to other recombinant endolysins make it a suitable candidate for development to replace antibiotics targeting harmful Staphylococci, including MRSA.